Neimeth Reports 26% Revenue Growth in H1 2026

Neimeth International Pharmaceuticals Plc emerged as the fastest-growing listed pharmaceutical company by revenue in the first half of 2026, achieving a 26% year-on-year increase in sales, totaling N3.66 billion, up from N2.91 billion in H1 2025. This growth occurred despite a challenging environment characterized by high borrowing costs, inflation, and foreign exchange volatility.

While Fidson Healthcare Plc retained its leadership in revenue and profitability, Neimeth demonstrated the strongest top-line growth, indicating effective market penetration and sustained demand for its products. The company's profit after tax increased to N207.66 million from N203.76 million in H1 2025, reflecting resilience amid rising interest rates and production costs.

Neimeth's gross profit rose by 15% to N1.82 billion, maintaining a healthy gross margin. Administrative expenses decreased by about 6%, showcasing improved operational efficiency.

Shareholders’ equity grew to N2.84 billion by June 2026, indicating a stronger capital position, although Neimeth remains the smallest by revenue, assets, and earnings compared to Fidson and May & Baker.